Irwin Goldstein, Anita H. Clayton, Andrew T. Goldstein, Noel N. Kim, Sheryl A. Kingsberg

Verlag Wiley-Blackwell, 2018

ISBN 9781119266150 , 376 Seiten

Format ePUB

Kopierschutz DRM

Geräte

Mehr zum Inhalt

Textbook of Female Sexual Function and Dysfunction - Diagnosis and Treatment

Kapitelkauf
Kurzinformation
Inhaltsverzeichnis
Leseprobe
Blick ins Buch
Fragen zum eBook

1
History of the International Society for the Study of Women’s Sexual Health (ISSWSH)

Sue W. Goldstein

Abstract

The International Society for the Study of Women’s Sexual Health (ISSWSH) emanated from a course assembling experts in different disciplines, becoming the model for the society. Seventeen years later the society remains multidisciplinary, with annual meetings featuring state of the art lectures, symposia on controversial topics, and abstracts judged on scientific merit. Educational efforts expanded from a half day precourse to a fall course and another in conjunction with the National Association of Nurse Practitioners in Women’s Health annually. Evidence‐based conferences have included consensus panels for nomenclature for desire, arousal, and orgasm; pain; genitourinary syndrome of menopause (GSM); clinical guidelines for identification of sexual health problems; and a process of care for the management of hypoactive sexual desire disorder. ISSWSH is now established as the leading organization for disseminating valuable information to providers, researchers and educators regarding management of distressing sexual dysfunction in women.

Keywords: ISSWSH; women’s sexual health; female sexual dysfunction; multidisciplinary; desire; arousal; orgasm; pain; GSM; nomenclature

The International Society for the Study of Women’s Sexual Health (ISSWSH) is the only professional organization dedicated to women’s sexual function and dysfunction. The society was founded less than two decades ago. Therefore, the history of the society is directly linked to the history of the field.

The approval of sildenafil in 1998 by regulatory agencies and a publication in the New England Journal of Medicine [1] led women to call urologist Irwin Goldstein to demand a medication for their sexual health problems. There was a paucity of information about the physiology of sexual function and the pathophysiology of sexual dysfunction in women, but Goldstein wanted to change that. Under the auspices of Boston University School of Medicine, he developed a course entitled New Perspectives in Female Sexual Dysfunction, assembling experts in different disciplines to share their information in an effort to piece together available knowledge. This became the model on which the society was developed three years later.

The course was held in the Boston area in 1998, 1999 and 2000. The first year there were over 200 registrants from around the world. Associated with the 1998 course, the American Foundation for Urologic Diseases sponsored a consensus conference with 19 international experts, resulting in the development of nomenclature for use in women’s sexual dysfunction [2]. Prior to this time all nomenclature was based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) of the American Psychiatric Association [3]. With the recognition of biologic components to sexual function, and the need to understand sexual dysfunction in women, the course was lengthened and podium and poster sessions added. Attendance doubled in 1999 with many returning registrants. When queried about interest in initiating a society, the response was negative. The following year, however, the group had an overwhelmingly positive response and the Female Sexual Function Forum was born.

The society was developed in a multidisciplinary manner with by‐laws designating that each committee and the board of directors be balanced in terms of gender, geography, and discipline. All disciplines with an interest in women’s sexual health would be welcome in the society, with all active members having equal import, regardless of profession, specialty or degree. Many members of the inaugural board continue to be active members, a testament to both the strength of and need for the organization. One of the first society benefits was the start of a moderated on‐line forum (ISSWSHNET) for difficult cases that facilitated communication among people from various locations, disciplines, and perspectives. Having gone through multiple iterations, ISSWSHNET remains a benefit for society members.

The format of the first meeting set the tone for future meetings, with state of the art lectures, symposia on controversial topics, and abstracts judged on scientific merit for podium or poster presentation. The hot topic through the first several annual meetings was the use of androgens in women, transitioning later to oral contraceptives and sexual dysfunction. The first business meeting and election were held on 28 October 2000, with Sandra Leiblum voted in as the first president (Figure 1.1).

Figure 1.1 Sandra Leiblum, PhD, first president of the International Society for the Study of Women’s Sexual Health, presiding over the business meeting.

After a year as the Female Sexual Function Forum it was noted that the word “female” could refer to animals, so, in 2001, the organization was renamed the International Society for the Study of Women's Sexual Health. Alessandra Graziottin from Italy ascended to the presidency but the board remained stable to help the fledging society. Only active or honorary members could serve on the board or as committee chairs, as affiliate members were associated with industry. The society struggled financially but survived through the fierce passion of the board and the support of its management company.

Nearly 400 people attended the 2002 meeting in Vancouver – the first time this group met away from Boston. Held shortly after the publication of the widely publicized Women’s Health Initiative [4], the leadership responded by adding a lunch seminar to disseminate accurate information and help dispel myths propagated by the press. Symposia were designed to span both the biological and psychological realms in the basic science and clinical arenas. While moving the 2003 meeting to Amsterdam was exciting, it put the society at risk, with a decrease in attendance and increase in meeting costs. Under Cindy Meston’s leadership, a development committee was established to seek industry support to help underwrite the conference, as is common among many other societies, with the long term goal of financial stability.

Lorraine Dennerstein put her presidential stamp on the society by recruiting young researchers in an attempt to grow both the society and the field. With the return to the United States in 2004 the society collaborated with the National Institutes of Health, cosponsoring the meeting “Vulvodynia and Sexual Pain Disorders in Women” held the day before the Atlanta ISSWSH meeting [5]. For the first time, several pharmaceutical companies arranged their advisory board meetings around the annual meeting, thus supporting ISSWSH financially and giving increased visibility to the young society. A half‐day precourse on the “Practical Management of Women’s Sexual Dysfunction” preceded the annual meeting, a response to the increasing demand for instruction for both the novice and advanced health‐care provider. The precourse enrollment that first year exceeded expectations with 160 attendees. The board responded by naming an education committee to develop a program of educational courses during the annual meeting, as well as a free‐standing three‐day course to be held at another time of year.

With these changes ISSWSH was beginning to make its true mark on the field of medicine. In 2005, ISSWSH was under the leadership of its first male president, Stan Althof, and in 2006 the annual meeting moved from October to February, in an attempt to find a dedicated time slot not conflicting with other societies, leaving the October time available for the three‐day educational “Fall Course”. The rotation of east coast, west coast, Europe for annual meetings would continue for a few years (Table 1.1), until it made more financial sense to stay in the United States, as attendees and drug development programs were based in the United States, allowing for growth of sponsorship opportunities.

Table 1.1 Dates and locations of ISSWSH annual meetings and the presidents at that time.

Term

President

Meeting location

2000–2001

Sandra R. Leiblum, PhD

Boston, MA (10/01)

2001–2002

Alessandra Graziottin, MD

Vancouver, Canada (10/02)

2002–2003

Cindy M. Meston, PhD, IF